Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta Therapeutics (NASDAQ:SRPT) surges 40% post-market after strategic restructuring, workforce cuts, pipeline focus, and ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...

In the preceding three months, 38 analysts have released ratings for Sarepta Therapeutics (NASDAQ:SRPT), presenting a wide array of perspectives from bullish to bearish. The table below provides a ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

Sarepta Therapeutics (SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, ...

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best low priced pharma stocks to buy now. Towards the end of June, ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the August 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...